SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Promise and Pitfalls of Biomedical Prevention: Beyond Phase III
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
Introduction
Linda-Gail Bekker
Desmond Tutu HIV Foundation, Cape Town, South Africa
Bruno Spire
Institut National de la Santé et de la Recherche Médicale, Marseille, France
Why Is Cabotegravir Rollout So Slow? (ABSTRACT
48)
Rupa R. Patel
Centers for Disease Control and Prevention, Atlanta, GA, USA
The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III (ABSTRACT
49)
Leila E. Mansoor
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
Challenging the Dogma of Event-Driven PrEP (ABSTRACT
50)
Jenell Stewart
Hennepin Healthcare Research Institute, Minneapolis, MN, USA
Panel Discussion
Linda-Gail Bekker
Desmond Tutu HIV Foundation, Cape Town, South Africa
Bruno Spire
Institut National de la Santé et de la Recherche Médicale, Marseille, France
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
